The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A vaccine to prevent AIDS is urgently needed. The European Union recently awarded over 20 million euros to a European consortium, called EAVI2020, to advance multiple HIV vaccines into human testing. Five Australian HIV vaccine experts are named investigators on this award to provide advanced laboratory analyses and intellectual input into the 5 year program if this NHMRC-EU Collaborative Research Grant is successful.
OptiMalVax: Optimizing A Deployable High Efficacy Malaria Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$494,618.00
Summary
In this proposal, a consortium comprising many of the leading malariologists, vaccine researchers and product developers in Europe, USA, Australia and Africa will collaborate in an exciting programme of antigen discovery science linked to rapid clinical development of new vaccine candidates against malaria.
Comparative Expression Studies To Identify Cellular Factors Promoting Hendra Virus Replication For A Comprehensive Understanding Of Hendra Virus Pathogenesis
Funder
National Health and Medical Research Council
Funding Amount
$374,619.00
Summary
Hendra virus (HeV) is an emerging pathogen indigenous to fruit bats. HeV is associated with limited outbreaks with high mortality in domesticated animals and humans. To advance the understanding of HeV-related pathogenesis, we will perform comparative studies in bat and human cell lines to recognise differences in virus-host cell interactions leading to a comprehensive understanding of the HeV life cycle and pathogenesis.
Reducing Peer Victimisation In Australian Schools Through Targeted And Universal Approaches
Funder
National Health and Medical Research Council
Funding Amount
$1,063,531.00
Summary
Peer victimisation is a significant problem for young people in Australia and can lead to devastating long-term consequences including poor self esteem, depression and suicide. The current project aims to identify the most cost effective methods to reduce peer victimisation in schools. This will combine programs applied across the whole school with a more targeted program building resilience in vulnerable children. The results will have important implications for anti-bullying policies in school ....Peer victimisation is a significant problem for young people in Australia and can lead to devastating long-term consequences including poor self esteem, depression and suicide. The current project aims to identify the most cost effective methods to reduce peer victimisation in schools. This will combine programs applied across the whole school with a more targeted program building resilience in vulnerable children. The results will have important implications for anti-bullying policies in schools.Read moreRead less
Hendra virus (HeV) cause a disease transmitted from bats to horses which in turn infect humans and other horses. There are no drugs or vaccines for HeV. Since humans are infected by inhalation, a vaccine that can generate antibody in the lung and protect from infection will be ideal. We have found that a natural sugar called mannan used with virus proteins and administered via the nostrils to generate such responses. In this project we will prepare this vaccine and use it in a mouse model of HeV ....Hendra virus (HeV) cause a disease transmitted from bats to horses which in turn infect humans and other horses. There are no drugs or vaccines for HeV. Since humans are infected by inhalation, a vaccine that can generate antibody in the lung and protect from infection will be ideal. We have found that a natural sugar called mannan used with virus proteins and administered via the nostrils to generate such responses. In this project we will prepare this vaccine and use it in a mouse model of HeV infection to see if it can protect the mice.Read moreRead less
Defining The Role Of MiR-146a In Human Hendra Virus Infections
Funder
National Health and Medical Research Council
Funding Amount
$348,998.00
Summary
This project aims to improve the medical management of people infected with Hendra virus by defining potential therapeutic windows for treatment with antiviral strategies. The project involves the study of microRNAs, a class of small ribonucleic acid molecules that regulate biological processes in eukaryotes. We will determine the role of microRNAs in the Hendra virus infection process in humans, and their application as diagnostic markers of Hendra virus infection.
Improving Adolescent Gate-keeping And Help-seeking For Risky Drinking And Depression: A Cluster Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$655,495.00
Summary
Young people with mental health and substance use problems are reluctant to seek help. There is a significant gap in health promotion activities which specifically target help-seeking skills, particularly teaching friends to help friends to access treatment early. This project seeks to demonstrate the efficacy of a school-based intervention that focuses on improving adolescent gate-keeping and help-seeking skills for risky drinking and depression, using a cluster randomised controlled design.
Determining The Clinical Effectiveness Of Antiviral Drugs Against Oseltamivir- And Laninamivir-resistant Influenza Viruses In Animal Models
Funder
National Health and Medical Research Council
Funding Amount
$388,067.00
Summary
Currently, the neuraminidase inhibitors are the only drugs that are effective against seasonal influenza viruses. However, viruses can develop resistance to these drugs. Using viruses with varied levels of resistance, the project will determine the effectiveness of different drug treatments in animal models. This will lead to better treatment for those patients seriously ill with drug-resistant influenza viruses.